China's Plan to Exempt More Devices From Trials Will Save Companies Effort And Cost
This article was originally published in SRA
Executive Summary
China's Food and Drug Administration is inviting feedback on a new batch of medium- and high-risk medical devices that it intends to exempt from having to undergo local clinical trials1. The agency's proposal, if adopted, would make it much easier and less costly for companies that want to place these devices on the Chinese market2.
You may also be interested in...
China's Medtech Regulatory Reforms Yet To Enter Steady Path
Medical device companies operating in China are still looking for clearer guidance that will help them make the most of the wide-ranging regulatory reforms introduced in the country since 2014.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.